Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) Equity Average (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Equity Average for 4 consecutive years, with $446.0 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 15.7% to $446.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $446.0 million through Dec 2025, down 15.7% year-over-year, with the annual reading at $472.0 million for FY2025, 11.14% up from the prior year.
  • Equity Average for Q4 2025 was $446.0 million at Day One Biopharmaceuticals, down from $455.9 million in the prior quarter.
  • The five-year high for Equity Average was $529.1 million in Q4 2024, with the low at $301.8 million in Q2 2024.
  • Average Equity Average over 4 years is $396.8 million, with a median of $376.9 million recorded in 2022.
  • The sharpest move saw Equity Average dropped 16.92% in 2024, then skyrocketed 55.81% in 2025.
  • Over 4 years, Equity Average stood at $347.6 million in 2022, then increased by 5.91% to $368.1 million in 2023, then soared by 43.75% to $529.1 million in 2024, then decreased by 15.7% to $446.0 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $446.0 million, $455.9 million, and $470.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.